FDA Approval Summary: Margetuximab plus Chemotherapy for Advanced or Metastatic HER2-Positive Breast Cancer
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
On December 16, 2020, the FDA granted regular approval to margetuximab-cmkb (MARGENZA), in combination with chemotherapy, for the treatment of adult patients with HER2-positive (HER2+) metastatic breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. Approval was based on data from SOPHIA, a multicenter, randomized, open-label, active controlled study comparing margetuximab with trastuzumab, in combination with chemotherapy. The primary efficacy endpoint was progression-free survival (PFS) by blinded independent central review. SOPHIA demonstrated a 0.9-month difference in median PFS between the two treatment arms [5.8 vs. 4.9 months, respectively; stratified HR, 0.76 (95% confidence interval: 0.59–0.98; P = 0.0334)]. Overall survival (OS) was immature at the data cut-off date of September 10, 2019. Infusion-related reactions (IRR) are an important safety signal associated with margetuximab plus chemotherapy. In SOPHIA, 13% of patients treated with margetuximab plus chemotherapy reported IRRs, of which 1.5% were grade 3. The most commonly reported adverse drug reactions (>10%) with margetuximab in combination with chemotherapy were fatigue/asthenia, nausea, diarrhea, vomiting, constipation, headache, pyrexia, alopecia, abdominal pain, peripheral neuropathy, arthralgia/myalgia, cough, decreased appetite, dyspnea, IRR, palmar-plantar erythrodysesthesia, and extremity pain. Overall, the favorable risk-benefit profile for margetuximab when added to chemotherapy supported its approval for the intended indication.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
Swain, S. M., Baselga, J., Kim, S.-B., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.-M., Schneeweiss, A., Heeson, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1413513 · Cited by 2,164
Trastuzumab deruxtecan in previously treated HER2-positive breast cancer
Modi, S., Saura, C., Yamashita, T., Park, Y. H., Kim, S.-B., Tamura, K., Andre, F., Iwata, H., Ito, Y., Tsurutani, J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1914510 · Cited by 2,006
Self-citationTucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer
Murthy, R. K., Loi, S., Okines, A., Paplomata, E., Hamilton, E., Hurvitz, S. A., Lin, N. U., Borges, V., Abramson, V., Anders, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1914609 · Cited by 1,326
Saura, C., Oliveira, M., Feng, Y.-H., Dai, M.-S., Chen, S.-W., Hurvitz, S. A., Kim, S.-B., Moy, B., Delaloge, S., Gradishar, W., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00147 · Cited by 604
Cited by
Targeting Breast Cancer: An Overlook on Current Strategies
Iacopetta, D., Ceramella, J., Baldino, N., Sinicropi, M., & Catalano, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043643 · Cited by 88
“Recently, the combination of margetuximab or T-DXd with small molecule inhibitors such as TKIs has been suggested to further improve the efficacy of monoclonal antibodies in the treatment of HER2+ MBC patients [225].”
BackgroundInfluentialIntratumoral implantable drug delivery system for targeted localized chemotherapy in breast cancer
Souri, M., Elahi, S., & Soltani, M. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.105519 · Cited by 31
Souri, M., Elahi, S., & Soltani, M. (2024) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2024.2323211 · Cited by 28
Metadata
- Authors
- Royce, M., Osgood, C. L., Amatya, A. K., Fiero, M. H., Chang, C. J. G., Ricks, T. K., Shetty, K. A., Kraft, J., Qiu, J., Song, P., Charlab, R., Yu, J., King, K. E., Rastogi, A., Janelsins, B., Weinberg, W. C., Clouse, K., Borders-Hemphill, V., Brown, L., Gomez-Broughton, C., Li, Z., Nguyen, T. T., Qiu, Z., Ly, A.-T., Chang, S., Gao, T., Tu, C.-M., King-Kallimanis, B., Pierce, W. F., Chiang, K., Lee, C., Goldberg, K. B., Leighton, J. K., Tang, S., Pazdur, R., Beaver, J. A., & Amiri-Kordestani, L.
- Venue
- Clinical Cancer Research
- Published
- 2021-12-16
- Volume
- 28
- Issue
- 8
- Pages
- 1487-1492
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W4200438498
- Cited by
- 37
- References
- 4
- FWCI
- 2.77
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: FDA Approval Summary: Margetuximab plus Chemotherapy for Advanced or Metastatic HER2-Positive Breast Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-21-3247
- The paper
- Royce, M., Osgood, C. L., Amatya, A. K., Fiero, M. H., Chang, C. J. G., Ricks, T. K., Shetty, K. A., Kraft, J., Qiu, J., Song, P., Charlab, R., Yu, J., King, K. E., Rastogi, A., Janelsins, B., Weinberg, W. C., Clouse, K., Borders-Hemphill, V., Brown, L., . . . Amiri-Kordestani, L. (2022). FDA Approval Summary: Margetuximab plus Chemotherapy for Advanced or Metastatic HER2-Positive Breast Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-21-3247
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.